MELAS syndrome
Methodology & AI Transparency ⓘ
MELAS syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of MELAS syndrome (E88.41) in Weight & Metabolism relies on incretin therapy candidacy in MELAS syndrome (E88.41: review), guiding step-wise therapeutic adjustments toward Waist-to-Height Ratio [MELAS syndrome E88.41] (< 0.50 (E88.41)).
- 2 Real-world patient consensus: Clinical coding for MELAS syndrome uses ICD-10 E88.41 across Weight & Metabolism specialty care.
- 3 Typical cash cost range: Differential triage of MELAS syndrome (E88.41) utilizes incretin therapy candidacy in MELAS syndrome (E88.41: review).
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for MELAS syndrome (E88.41): DEXA Visceral Adipose in MELAS syndrome (E88.41: Tissue (VAT)) & Waist-to-Height Ratio [MELAS syndrome E88.41] (< 0.50 (E88.41)).
Ask our AI Specialists anything about MELAS syndrome
What Is MELAS syndrome?
Clinical triage of MELAS syndrome (E88.41) in Weight & Metabolism relies on incretin therapy candidacy in MELAS syndrome (E88.41: review), guiding step-wise therapeutic adjustments toward Waist-to-Height Ratio [MELAS syndrome E88.41] (< 0.50 (E88.41)).
Pathophysiology, Underlying Causes & Clinical Presentation
MELAS syndrome (E88.41) alters weight & metabolism homeostasis through pro-inflammatory adipokine signaling in MELAS syndrome (E88.41: (IL-6); clinical remission targets Waist-to-Height Ratio [MELAS syndrome E88.41] within < 0.50 (E88.41).
Common Symptoms & Clinical Signs
- • Presentation of MELAS syndrome (E88.41): daytime sluggishness or in MELAS syndrome (E88.41: loud snoring linked)
- • Secondary MELAS syndrome clinical sign: central abdominal visceral in MELAS syndrome (E88.41: fat accumulation resistant)
- • Symptom flares in MELAS syndrome correlating with DEXA Visceral Adipose in MELAS syndrome (E88.41: Tissue (VAT)) deviation outside < 1.0 lb (< 100 cm2) (E88.41)
- • Functional weight & metabolism impact requiring incretin therapy candidacy in MELAS syndrome (E88.41: review) evaluation (E88.41)
MELAS syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.41 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in MELAS syndrome (E88.41: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [MELAS syndrome E88.41] | < 0.50 (E88.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in MELAS syndrome (E88.41: Index) | < 1.4 (E88.41) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for MELAS syndrome
Treatment selection for MELAS syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (MELAS syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight: What a 3,731-Participant Study Found In this study, 3.0 mg of liraglutide, as an add-on booster to diet and exercise, was associated with reduced body weight and improved metabolic control. The New England journal of medicine • 2015-07-02 • Randomized Controlled Trial | N = 3,731 | 96/100 | PMID 26132939 ↗ |
| New Insights on Safety, tolerability and sustained weight loss over 2 years with the once-daily: What a 564-Participant Study Found Liraglutide is well tolerated, sustains weight loss over 2 years and improves heart and blood vessel risk factors. International journal of obesity (2005) • 2012-06-15 • Randomized Controlled Trial | N = 564 | 93/100 | PMID 21844879 ↗ |
| What the Latest Evidence Really Says About Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists Of 7705 unique records, 41 articles representing 64 RCTs were included in the meta-analysis. JAMA internal medicine • 2026-05-01 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41770554 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-acting PYY 3 -36 analogue with semaglutide for obesity: from preclinical PYY1875 showed modest efficacy as an add-on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated. Obesity (Silver Spring, Md.) • 2025-08-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 40629530 ↗ |
| What the Latest Evidence Really Says About Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Females lost more weight than males when treated with GLP-1RAs for weight reduction. Journal of diabetes • 2025-03-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40040445 ↗ |
MELAS syndrome Patient Community & “People Like Me” Threads
Filter MELAS syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.